Medicare drug spending figures include the fees collected by doctors, hospitals and wholesalers. Azar wants to import this price control model by indexing Medicare drug payments to the average sales prices of drugs in 14 other developed nations. By delaying drug launches, price controls would condemn many American patients to early, avoidable deaths. Taxpayers would suffer too since price controls would prevent the creation of new treatments that reduce overall health spending. But these drugs may never exit the lab if the United States imposes price controls on pharmaceuticals.

Source: Fox News February 03, 2019 19:54 UTC